Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review
Journal of Clinical Ophthalmology and Research · 2026-10 · 14 (4) · 475-482
DOI: 10.4103/jcor.jcor_265_26 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Ophthalmology and Research, online erschienen am 18.11.2026. Verfasst von Bhavya Yarlagadda und 2 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Glaucoma is the leading cause of irreversible blindness, with intraocular pressure (IOP) reduction acting as the sole modifiable risk factor. While topical prostaglandin analogs (PGAs) serve as first-line therapies, they are frequently limited by poor adherence, preservative-related toxicity, and subtherapeutic dosing. This systematic review evaluated the efficacy, safety, and drug delivery performance of the Food and Drug Administration-approved travoprost intracameral implant (iDose TR), which provides continuous, preservative-free medication directly into the anterior chamber. Following Preferred Reporting Items for Systematic Reviews and MetaAnalyses 2020 guidelines, a comprehensive literature search was conducted across PubMed, Scopus, Cochrane Cochrane Central Register of Controlled Trial, and EMBASE through August 2025 to identify peer-reviewed clinical trials and real-world studies reporting on IOP, drug burden, or safety in open-angle glaucoma or ocular hypertension. Eight studies encompassing 1457 patients were analyzed. In Phase 3 trials, the slow-eluting implant demonstrated noninferiority to timolol 0.5% BID up to 3 months, achieving a mean IOP reduction of 6.0–7.5 mmHg. By 12 months, 81% of implant eyes remained medication-free, and the implant outperformed prestudy topical PGA monotherapy by an additional 1.31 mmHg reduction ($p = 0.0003$). Phase 2b data confirmed sustained 36-month effectiveness and stable corneal endothelial cell density (ECD), whereas real-world data showed a 33.2% mean IOP reduction at 3 months. Ultimately, the travoprost intracameral implant represents an effective sustained-release platform that overcomes adherence and bioavailability barriers. However, given that real-world data are currently limited to short-term (3-month) follow-up, conclusions regarding long-term safety, particularly ECD, must be interpreted with caution.
Zitieren
APA
Yarlagadda, B., Kakde, P. P., & Govindan, S. (2026). Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review. Journal of Clinical Ophthalmology and Research, 14(4), 475-482. https://doi.org/10.4103/jcor.jcor_265_26
Vancouver
Yarlagadda B, Kakde PP, Govindan S. Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review. Journal of Clinical Ophthalmology and Research. 2026;14(4):475-482. doi:10.4103/jcor.jcor_265_26
BibTeX
@article{Yarlagadda2026,
author = {Yarlagadda, Bhavya and Kakde, Pranotti Pramodkumar and Govindan, Susaritha},
title = {Efficacy and safety of sustained-release intracameral travoprost implant (iDose TR) for open-angle glaucoma and ocular hypertension: A systematic review},
journal = {Journal of Clinical Ophthalmology and Research},
year = {2026},
volume = {14},
number = {4},
pages = {475--482},
doi = {10.4103/jcor.jcor_265_26}
}
EUVIMED